Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 3, 1997, Pages 199-201

  Pfaller, Michael A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLONE DERIVATIVE; RIFAMPICIN; SPARFLOXACIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; HEMOLYTIC STREPTOCOCCUS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0030696294     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)81810-X     Document Type: Article

References (20)

1. Alcaide F, Linares J, Pallares R (1995) In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 39:2243-2247.
2. Allegra L, Konietzko N, Leophonte P (1996) Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomized, parallel, multicentre study. J Antimicrob Chemother 37:93-104.
3. Aubier M, Lode H, Gialdroni-Grassi G (1996) Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies. J Antimicrob Chemother 37:73-82.
4. Baquero F, Canton R (1996) In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 37:1-18.
5. Bochud PY, Eggiman P, Calandra T, Van Melle G, Laghafi L, Francioli P (1994) Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31.
6. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR (1994) Emergence of drug-resistant pneumococcal infections in the United States. J Am Med Assoc 271:1831-1835.
7. Doern GV, Brueggeman A, Holley Jr HP, Rauch AM (1996a) Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208-1213.
8. Doern GV, Ferraro MJ, Brueggeman AB, Ruoff KL (1996b) Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891-894.
9. Ferrieri P, Kaplan EL (1992) Invasive group A streptococcal infections. Infect Dis Clin North Am 6:149-161.
10. Fu KP, Lafredo SC, Foleno B (1992) In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 36:860-868.
11. Gehanno P, Berche P, The Sinusitis Study Group (1996) Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J Antimicrob Chemother 37(suppl A):105-114.
12. Jernigan DB, Cetron MS, Breiman RF (1996) Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): A strategy from the DRSP working group. J Am Med Assoc 275:206-209.
13. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluoroquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
14. Kern W, Linzmeier K, Kurrie E (1989) Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection 17:396-397.
15. McWhinney PHM, Patel S, Whiley RA, Hardie JM, Gillespie SH, Kibbler CC (1993) Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother 37:2493-2495.
16. National Committee of Clinical Laboratory Standards (NCCLS) (1995) Performance Standards for Antimicrobial Susceptibility Testing. Supplemental Tables, M100-S6. Villanova, PA: NCCLS.
17. National Committee of Clinical Laboratory Standards (NCCLS) (1993) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically (3rd ed). Approved Standard M7-A3. Villanova, PA: NCCLS.
18. Richard P, Gutmann L (1992) Sparfloxacin and other new fluoroquinolones. J Antimicrob Chemother 30:739-744.
19. Sutton LD, Jones RN (1995) Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates. J Clin Microbiol 33:146-148.
20. Wise R, Child J, Mortiboy D, Chow A (1995) An open-label, cross-over study of the pharmacokinetics and tissue penetration of two dose regimens of levofloxacin (abstr. A54). Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, p. 11.